Using the Affymetrix array technology, we previously identified an EST strongly expressed in several metastatic cell lines. In the present study, we cloned the corresponding cDNA that encodes a new glycoprotein composed of 97 amino acids and containing a trans-membrane domain. Therefore, we named it SMAGP for Small transMembrane And Glycosylated Protein. SMAGP is strongly conserved during evolution. It is expressed by normal epithelia of various organs, the protein being notably localized to the lateral face of the plasma membrane of cohesive well-polarized epithelial cells. In addition, SMAGP contains binding domains for the protein 4.1 and the PDZ domain of MAGUK proteins. Similar protein features are observed in several cellsurface proteins involved via ternary complexes in intercellular processes leading to cytoskeleton assembly as well as intracellular signalling. Thus, SMAGP might similarly be involved in a scaffolding protein complex, and therefore participate in the epithelium organization or in subsequent functions. Immunohistochemical data obtained using human breast, colon and lung cancer samples sustain this hypothesis since they showed that, in both primary tumours and metastases, reduced expression and/or cytoplasmic redistribution of SMAGP is superimposable with low histological tumour differentiation features, namely a lack of epithelial cell polarity and disorganized tissue phenotype.
Introduction
The formation of metastases is the crucial step in the progression of cancer since they are directly responsible, rather than primary tumours, for most cancer deaths. Therefore, new diagnostic markers and improved therapies against tumour progression and metastasis are urgently needed to increase the survival rate of cancer patients.
The metastatic process is a cascade of sequential steps which must all be successfully completed. The first step consists of the detachment of cancer cells from the primary tumour, followed by the degradation and invasion of the extracellular matrix (ECM) and neighbouring tissues. Once tumour cells succeeded to penetrate and survive in the lymphatic and/or the vascular system, they may arrest to a secondary site due to physical limitations (e.g. capillary size) and their ability to grow is dictated by molecular interactions of the cells with the environment in the organ (e.g. chemokines activation). Finally, recruitment of vascular supply is required to form macroscopic metastases (Welch, 1997; Chambers et al., 2002) .
According to the great number of distinct cellular and molecular processes involved in metastasis progression, metastatic cells frequently display a large range of gene alterations that contribute to their metastatic potential. This includes activation of oncogenes, recruitment of metalloproteinases and motility factors, as well as changes in the expression and/or functionality of multiple adhesion molecules (Hunter et al., 2001; Skubitz, 2002) . In addition, eight genes known as metastasis suppressors have been described (Steeg, 2003) . Despite the steadily increasing knowledge in this field (Greenwood, 2003; Kang et al., 2003) , many critical genetic and biochemical events involved in the metastatic process remain to be determined.
The availability of isogenic tumour cell lines with marked differences in metastatic behaviour offers a good model to study the metastatic process. The rat tumour cell system BSp73, comprising two stable variants derived by serial transplantation of a spontaneous rat pancreatic tumour: the nonmetastatic BSp73-AS variant and the metastatic BSp73-ASML variant (Matzku et al., 1983) . Previous studies have demonstrated that it constitutes an appropriate cellular model to identify metastasis-associated genes. Monoclonal antibodies were raised against membrane proteins of the metastatic BSp73-ASML cell line in order to identify surface molecules associated with the metastatic phenotype, and four proteins (CD44v, D6.1A, C4.4A and EGP314) only present on the surface of the metastastic variant were identified. Their involvement in the metastasis process was demonstrated using stable transfectants of several nonmetastasizing tumour cells.
Gene expression was sufficient to either confer metastatic potential or to promote distinct steps of the metastatic cascade (Gunthert et al., 1991; Claas et al., 1998; Rosel et al., 1998; Wurfel et al., 1999) . Furthermore, the deregulated expression of CD44v has been correlated to a poor prognosis in many human cancers (Sy et al., 1997) . Even more metastasis-associated candidate genes were identified in this cell system with the subtractive suppression hybridization (SSH) technology coupled to a high-throughput screening protocol (Nestl et al., 2001) .
Recently, in order to identify novel genes involved in tumour progression and metastasis, we derived the transcriptional profile of the two BSp73 variants using the Affymetrix array technology of Genechip and could extend the panel of metastasis-associated candidate genes (Tarbe´et al., 2002) . We identified 1555 ESTs as deregulated in BSp73-ASML in comparison to BSp73-AS, with 628 and 927 ESTs up-and downregulated, respectively. The majority of the deregulated ESTs exhibited a fold change of 3-50, with maximal values over 1000 (Tarbe´et al., 2002 ). An EST of 528 bp (Accession No. AA851961) with a strong overexpression of the corresponding mRNA in the metastatic variant BSp73-ASML and no homology to known eucaryotic genes was selected for further characterization.
In this study, we report the cloning of the corresponding cDNA and the characterization of the encoded protein. It is a new small trans-membrane glycoprotein that we named SMAGP (Small trans-Membrane And Glycosylated Protein), and that is strongly conserved during evolution. Further analyses showed that the protein is mainly localized to the lateral part of plasma membranes in normal epithelial structures. During tumour progression, SMAGP expression level and localization are either conserved, or altered in association with epithelial structure disorganization.
Results

SMAGP, a new cDNA highly conserved during evolution
In order to assemble the full-length cDNA sequence, we carried out an homology search in EMBL database. Overlapping homology regions were identified between the candidate EST (Accession No. AA851961) and three different rat EST sequences (Accession Nos. AI178855, BE101414 and BF556978), and a 827 bp cDNA consensus sequence was obtained after alignment. Completion of the sequence was accomplished by RACE-PCR to a length of 1.5 kb. The resulting cDNA was designated as rSMAGP (rat Small trans-Membrane And Glycosylated Protein) and was registered in EMBL Genbank under the Accession No. AJ577837. The rSMAGP cDNA sequence spans 1501 bp and contains a single open reading frame (ORF) of 294 bp (Figure 1 ). The 5 0 untranslated region is composed of 57 nucleotides and the translation initiation start codon with its surrounding nucleotides match the Kozak consensus sequence (Kozak, 1984) . The 3 0 untranslated region of 1153 bp is characterized by three putative polyadenylation signals downstream of the translation stop codon at positions 640 (AATAA), 1032 (AATAA) and 1392 bp (ATTAA). It seems that the use of the third polyadenylation signal is preferential since only a unique band at 1.5 kb is detected by Northern blotting analysis. Multiple polyadenylation sites have been described for numerous genes but their biological significance is still unclear (Rogers et al., 1997; Jeanplong et al., 2001 ). We performed a search in EMBL database to investigate the conservation of SMAGP in other species. Orthologue cDNAs were identified in Homo sapiens and Mus musculus (Accession Nos. BN000259 and BN000260, respectively). Further strong homology was noted with ESTs isolated from Bos taurus, Sus scrofa, Xenopus laevis and Brugia malayi. The corresponding nucleotide sequences were assembled from EST alignments and have been submitted to EMBL Genbank under the Accession Nos. BN000261, BN000262, BN000263 and BN000264, respectively. The SMAGP Figure 1 Nucleotide sequence and putative protein sequence of rSMAGP. The putative translation initiation codon (ATG) is underlined, the stop codon (TAA) is bold underlined, and the putative three polyadenylation signals of the 1501 bp long cDNA are waved underlined. The putative amino-acid sequence of rSMAGP spans 97 amino acids. The protein contains a predicted type III signal anchor sequence (Nielsen et al., 1999) characterized by a long hydrophobic domain (trans-membrane domain in bold characters) followed by a positively charged C-terminal region. The N-terminal extracellular part contains six putative O-glycosylation sites (boxed) and the C-terminal cytoplasmic tail contains one putative protein kinase C (S 86 ) and one putative tyrosine kinase (Y 95 ) phosphorylation sites (both double underlined) nucleotide sequences identified from seven distinct eucaryotic species (human, rat, mouse, cow, pig, frog and worm) exhibit an average homology score of 471%. The score reaches at least 85% in the 294 bp ORF region. During this study, sequencing of the Rattus norvegicus genome was completed that allowed the localization of the rSMAGP gene to chromosome 7. Four exons of 22, 69, 81 and 1329 bp were identified, and the 294 bp ORF is spread over exons 2-4. Similarly, the human SMAGP gene could be located on the reverse complementary strand of the long arm region 13 of chromosome 12 (12q13.12) using the human genome databank. Again, four exons of 126, 74, 81 and 759 bp were identified, and the 294 bp ORF is spread over exons 2-4. The SMAGP gene is localized in rat and human chromosomal regions which are characterized by syntenic conservation.
Analysis of SMAGP amino-acid sequence and protein organization
The ORF encodes a protein composed of 97 amino acids with an estimated molecular mass of 10.6 kDa and a pI of 4.03. The protein contains a predicted type III signal anchor sequence characterized by a long hydrophobic domain (21 residues) followed by a positively charged Cterminal tail (42 residues) that defines a N exo /C cyto topology (Wahlberg and Spiess, 1997; Nielsen et al., 1999) . The short N-terminal extracellular region contains 34 residues and six potential O-glycosylation sites, whereas no N-glycosylation sites are predicted. The cytoplasmic tail contains one putative protein kinase C (S 86 ) and one putative tyrosine kinase (Y 95 ) phosphorylation sites (Figure 1 ).
The putative amino-acid sequences of the rSMAGP orthologues were deduced from the above identified cDNAs and aligned with rSMAGP protein. The nucleotide sequence of Brugia malayi is still incomplete, but a fragment of the putative protein could be identified and used for the alignment. The proteins display homology exceeding 80% (Figure 2a ). The rat and human protein sequences exhibit 80% identity and 84% similarity. Based on these observations we conclude that SMAGP is well conserved in eucaryotes.
In order to identify potential protein motifs, we performed a SwissBank database search. Protein homology for hSMAGP was revealed with the carboxyl-terminal regions of human protein glycophorin C (GPLC, 40% homology), nectin-like protein 1 (NECL1, 28%), nectin-like protein 2 (NECL2, 30%) and nectinlike protein 3 (NECL3, 41%) ( Figure 2b ). The binding regions for protein 4.1 and p55 within GPLC (amino acids 66-77 and 102-112) were found to be conserved to 50 and 63% in hSMAGP (amino acids 57-68 and 87-97), respectively. All aligned proteins display an identical four amino-acid C-terminal motif (EYFI). We noted that this motif is conserved in all SMAGP orthologues. Interestingly, the C-terminal YFI motif has been identified as a PDZ binding motif of class II (Songyang et al., 1993) that binds PDZ domains of the MAGUK (membrane-associated guanylate kinase homologues) proteins p55 and CASK (Marfatia et al., 1997; Biederer et al., 2002) . Thus, the C-terminal region of SMAGP contains potential binding regions for protein 4.1 and MAGUK proteins ( Figure 2c ).
Post-translational modifications of the SMAGP protein
To further characterize the SMAGP protein, a polyclonal antibody was raised against a synthetic peptide corresponding to the last 15 residues of the C-terminal part of hSMAGP, which are conserved to 80% between rat and human SMAGP. This antibody recognizes both rat and human SMAGP. Part of the residues of the synthetic peptide used to design the antibody constitutes an hapten (EKxEYFI) shared with GPLC and NECL proteins ( Figure 2b ). NECL2/SynCAM is known to be highly expressed by HEK293 cells (Masuda et al., 2002) and in brain (Biederer et al., 2002) , and a polyclonal antibody directed against the 11 last AA of synCAM (and therefore containing the same hapten) is commercially available (Novus Biologicals Inc., CO, USA). Thus, in order to test the specificity of the anti-SMAGP antibody, HEK293, HEK293 transfected with hSMAGP expressing vector, and rat brain extracts were loaded on a Western blot that was revealed using either SMAGP or synCAM antibodies. We observed that SMAGP antibody was specific of SMAGP since it was only able to detect SMAGP expressed by HEK293-transfected cells (Figure 3 , right panel, lane c). Moreover, two bands at approximately 11 and 25 kDa were observed suggesting that SMAGP might be posttranslationally processed. We noticed that the synCAM antibody cross-reacts with SMAGP ( Figure 3 , left panel, lane c).
SMAGP post-translational modification was then studied on endogenous protein using rat (MTLn3) and human (HCT116-cl5.5) tumour cell lines that constitutively express SMAGP. Western blot analysis of protein extracts showed a band corresponding to SMAGP of approximately 23 and 25 kDa, in rat and human cell lines, respectively (Figure 4 , lanes c and g). Thus, in both species SMAGP antibody recognized SMAGP at a size increased about twofold than the predicted molecular weight. No band was observed at the predicted 11 kDa size indicating that, in the previous experiment, the 11 kDa band should be due to the high amount of recombinant protein produced in transfected HEK293 cells. Since the SMAGP primary sequence contained several putative glycosylation sites, we performed similar Western blot analysis of protein extracts after deglycosylation with N-glycosidase F (PNGase F), sialidase and O-glycosidase. As expected, PNGase F treatment (Figure 4 , lanes d and h) had no effect on the apparent molecular weight, indicating that SMAGP is not N-glycosylated. Sialidase treatment (Figure 4 , lanes e and i) led to a small band shift, suggesting that SMAGP is modified by sialic acids. Additional Oglycosidase treatment (Figure 4 , lanes f and j) led to a pronounced shift in apparent molecular weight, consistent with the presence of O-glycosylation sites. Finally, treatment with O-glycosidase alone (Figure 4 , lane k) had no effect on the molecular weight of SMAGP, confirming the presence of sialic acids attached on O-linked oligosaccharides, which is known to inhibit the action of the O-glycosidase (Fukuda et al., 1987) . The N-glycosylated transferrin, alpha1-acid and Rnase B glycoproteins were used as positive controls for PNGase F treatment (Figure 4, lanes a and b) .
SMAGP expression and subcellular localization in normal tissues
The tissue distribution of SMAGP expression was evaluated in a panel of normal rat tissues by Northern blot analysis ( Figure 5) . A unique band at 1.5 kb was observed. The expression of SMAGP mRNA is relatively ubiquitous and the highest expression levels were detected in kidney and placenta. High expression was also detected in skin, breast, liver, lung, intestine, colon and prostate. No mRNA was detected in brain, pancreas, muscle, thymus and testis.
According to this expression pattern in rat, immunohistochemical experiments using the anti-SMAGP antibody on normal human breast, endometrium, colon and biliary tract tissues showed that the SMAGP protein is strongly expressed throughout these organs (Figure 6a-d, respectively) . SMAGP expression is restricted to the polarized epithelial structures characterized by cell-cell adhesion leading to cuboı¨dal cell morphology. In the cells, in addition to a low to moderate cytoplasmic staining, a striking staining was localized at the plasma membranes. Moreover, SMAGP is not randomly distributed along the whole plasma membrane, but mainly at membrane lateral parts located at the cell-cell epithelial junctions. The basal and apical membrane sides were often devoid of SMAGP.
SMAGP expression and subcellular localization in human primary tumours and metastases SMAGP mRNA expression was analysed in six primary tumours and six metastases from breast cancer patients Figure 5 Northern blot analysis for expression of SMAGP mRNA in rat normal tissues. Each lane was loaded with 20 mg total RNA from various organs as indicated. Autoradiography was for 3 days. Low to strong SMAGP expression is observed in almost all tissues studied with the exception of brain, pancreas, muscle, thymus and testis that were negative. Hybridization of the membrane with a 18S RNA probe was used as a loading control using Northern blot analysis ( Figure 7) . In both sets, the levels of 1.5 kb SMAGP transcript varied from one sample to another one, from negative (lanes 6 and 7) to highly positive (lanes 3, 5 and 9), the other samples showing low to moderate SMAGP expression. We next examined SMAGP protein in primary tumour and metastasis samples coming from 10 colon, 10 lung and 10 breast cancer patients. In all sets, the level of SMAGP expression can remain quite high or can be extremely reduced (Figure 8d Figure  8h and j), the normal pattern is lost simultaneously with the disappearance of the epithelial structures, SMAGP becoming totally cytoplasmic. Finally, for a given patient (Figure 8a and b, primary colon tumours; Figure  8g and h, liver metastases; Figure 6c , normal colon from the same patient), various SMAGP phenotypes can be observed in primary tumours and metastases, and even can coexist inside the same tumour depending on the differentiation status of the area tested. Thus, in all primary tumours and metastases studied, strong level of SMAGP cell membrane subcellular localization is superimposable to well-differentiated epithelial structures.
Discussion
Metastasis remains a permanent problem for patients with advanced cancers and new diagnostic markers and therapies are urgently needed to improve survival of cancer patients. In a previous study, making use of DNA chip technology, we have identified a candidate metastasis-associated EST (Tarbe´et al., 2002) . We now show that the corresponding cDNA encodes a new protein referred to as SMAGP for Small trans-Membrane And Glycosylated Protein. In fact, it is a transmembrane protein composed of 97 amino acids, which is post-translationally modified mainly by sialic acids and O-glycosylation. SMAGP is normally expressed in various organs in which it is restricted to epithelia. Moreover, in these highly organized and polarized structures, SMAGP is strikingly localized at the lateral side of the plasma membranes involved in epithelial cell-cell contacts. SMAGP is highly conserved Figure 8 Immunohistochemical analysis of SMAGP expression in human cancer tissues. (a-f) primary tumours from colon (A, B), lung (C, D), and breast (E, F). (g-j) liver (G, H) and lymph node (I, J) metastases. Tumours on the left column (A, C, E, G, I) are histologically well differentiated with partially conserved epithelial structures, whereas those on the right column (B, D, F, H, J) are poorly differentiated. Well-differentiated tumours exhibit strong SMAGP expression and the protein localisation to the plasma membrane is more or less conserved in cancer cells. By contrast, undifferentiated tumours were associated to a cytoplasmic localisation of the protein, and sometimes with a decreased SMAGP expression. A and B: primary tumour samples, and G and H: metastasis samples from the same colon cancer patient (Figure 6c : normal colon sample from the same patient). Magnification Â 100 Figure 7 Northern Blot analysis for expression of SMAGP mRNA in human breast cancers. Each lane was loaded with 10 mg total RNA. Autoradiography was for 1 week. Lanes 1 to 6: primary tumours; lanes 7 to 12: lymph node metastases. Negative or very low (lanes 6 and 7) to strong (lanes 3, 5 and 9) SMAGP expression is observed. Hybridization with a 36B4 probe was used as a loading control (Re´gnier et al., 1995) during evolution since appropriate orthologues were found in human, rat, mouse, cow, pig, frog and worm. Finally, the chromosomal localization and the gene organization are conserved between rat and human. Together, all these results strongly suggested that SMAGP might exert an important biological role presumably in epithelial organization or in subsequent function(s). This led us to investigate SMAGP expression during cancer progression since the majority of human cancers are carcinomas resulting from alteration of epithelial cells and structures.
Primary tumours, and lymph node and liver metastases from colon, mammary gland and lung cancer patients were studied. Immunohistological data showed that high SMAGP expression level and membrane subcellular localization similar to those observed in normal tissues were retained in tumours exhibiting relatively well-differentiated epithelial structures. On the opposite, diffuse cytoplasmic SMAGP localization were found in cancer cells of primary tumours as well as metastases exhibiting poor differentiation status characterized by disorganized or even absent epithelial organization. In addition, undifferentiated tumours can also show decreased levels of SMAGP expression. Moreover, for a given patient, the different phenotypes can coexist depending on the tumour and metastasis studied and, even for a given tumour, depending on the areas studied. Similar observations were done in breast, lung and colon cancers indicating that SMAGP alteration is not dependent to the nature of the concerned organ but a common event occurring during the course of cancer, in association with the loss of cell-cell junction, a prerequisite for cancer progression.
Epithelial tumour progression involves a series of cumulative alterations. Invasive and migratory properties should notably be acquired, enabling cells to pass from a sessile to a motile phenotype and to ultimately metastasize. During this process, disruption of cell-cell adhesion is a major event as well as alteration of cytoskeleton network. In this context, the presence of protein 4.1 and MAGUK binding sites in SMAGP suggests that, as some other cell-surface glycoproteins, SMAGP might be coupled to the actin cytoskeleton via a ternary membrane-associated complex, and might have therefore a function mediating membrane and cytoskeleton dynamics and cell signalling. In fact, it has been shown that MAGUK proteins are exerting an adapter function to stabilize the association of cellsurface glycoproteins to the cytoskeleton via protein 4.1 (Biederer and Sudhof, 2001 ). The subcellular localization of SMAGP to the lateral membrane at the cell-cell interface in normal epithelia, as well as the loss of this localization in association with the loss of epithelial structures in poorly differentiated tumour and metastasis areas, argues in favour of such an hypothesis.
The nature of the molecular mechanism(s) responsible for decreased expression and/or perturbation of SMAGP subcellular localization in cancer remains to be studied. The expression of SMAGP could be affected in tumours by either genetic or epigenetic alterations leading to a downregulation at the transcriptional level.
This could also indirectly result from altered gene expression due to altered transmission downstream cell-cell contacts (Fukata and Kaibuchi, 2001; Grille et al., 2003; Lozano et al., 2003) . Moreover, proteins destined for apical, basal or lateral cell-surface regions are sorted into distinct post-Golgi processes. Thus, modifications of the post-translational events could also have a major influence on the altered protein localization (Rodriguez-Boulan and Gonzalez, 1999) . Similar reduced expression and altered subcellular localization from membrane to cytoplasm in cancers was already reported for trans-membrane proteins. For example, the E-cadherin redistribution has been reported to be dependent from phosphorylation status of the protein (Nawrocki et al., 1998) . Finally, enzymatic cleavage at an intracellular site resulting in cytoplasmic fragments may also be involved.
In summary, SMAGP is a novel small trans-membrane glycoprotein related to cell-cell contacts in normally well-differentiated and polarized epithelial structures. SMAGP protein organization indicates its possible involvement in cytoskeleton assembly and cell signalling via a MAGUK-dependent ternary complex. SMAGP is affected during cancer progression, so that its plasma membrane localization is lost at the time of alteration of cell-cell adhesion, in low-differentiated primary and secondary tumours. Further investigations should clarify the nature of SMAGP partners and its role in the establishment and/or maintenance of the differentiated epithelial phenotype. Understanding the molecular mechanism(s) operating at cell-cell contacts might provide potential therapeutic targets to interfere with metastasis.
Materials and methods
Cell culture
Human embryonic kidney cell line HEK293 and colon adenocarcinoma cell line HCT116-cl5. 5 are available at Roche Diagnostics GmbH (Penzberg, Germany). The HCT116-cl5.5 was isolated in vivo from HCT116-derived lung metastases (Brattain et al., 1981) . These cell lines were cultured without antibiotics in RPMI 1640 supplemented with 10% foetal bovine serum and 2 mM L-glutamine. Rat mammary adenocarcinoma cell line MTLn3 (Neri et al., 1982; Nestl et al., 2001 ) was a gift of G Nicolson (Huntington Beach, USA) and was cultured in MEM-supplemented with 10% foetal bovine serum. All cell lines were free of mycoplasma contamination.
Transient transfection
Human SMAGP ORF was cloned in pcDNA3.1/Hygro. ( þ ) vector (Invitrogen AG, Switzerland). After linearization, pcDNA3.1/Hygro-hSMAGP was transfected with FugeneTM 6 into HEK293 cells. Cells transfected with empty vector were used as control.
Northern blotting
Total RNA was isolated from frozen tissues with RNeasy midi kit (Qiagen, Hilden, Germany). A measure of 10 mg of total RNA were size-separated on a denaturing 1% agarose formaldehyde gel and blotted (NorthernMax blotting kits, Ambion) onto nylon membrane (BrightStar-Plus, Ambion, Austin, USA). After UV-crosslinking (UV Stratalinker 2400, Stratagene, La Jolla, USA), blots were hybridized with [a-32 P]dATP-labelled cDNA as described previously (Tarbeé t al., 2002) . Equal loading of total RNA on agaroseformaldehyde gel was verified by ethidium bromide staining of ribosomal RNA, or 36B4 probing. Expression of SMAGP mRNA in rat normal tissues was determined by use of commercial rat total RNA blots (Northern Territory, Invitrogen, Huntsville, USA). Each lane was loaded with 20 mg total RNA and equal loading was checked by quantification of 18S RNA. Blots were processed as mentioned above. cDNA probes for the rat and human mRNA of SMAGP were realized with RT-PCR, using the primers pairs B1 (TTGTGGTATCCAGCCTCCA)/B2 (GGCTCCAACACT-GAGACACTG) and H105 (ACAAAGGCAGCTACGT-CACC)/H106 (CTTTCTCCATGTCCCTGGTC), respectively. The resulting probes correspond to a 290 and 295 bp region in the 3'UTR of rat and human SMAGP mRNA, respectively.
RACE-PCR
Full-length rSMAGP cDNA sequence was obtained with RACE-PCR using a SMART RACE cDNA Amplification kit (Clontech, Palo Alto, USA). A measure of 1 mg total RNA from BSp73-ASML cell line was reverse transcripted according to the manufacturer's instructions. The 5 0 and 3 0 untranslated regions were amplified by PCR with Clontech Universal primers and rSMAGP sequence-specific primers B140 (5 0 -GAT GAA GTA CTC TTC CTT CTC TTT GC-3 0 ) and B139 (5 0 -AAG GGG AGC CCA GCG CCA TCC TCC AG-3 0 ), respectively. The PCR products were cloned into pCR4-TOPO vector (Invitrogen) and sequenced with ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, USA).
Analysis of sequences
BLAST (Altschul et al., 1997) was used for homology searches against nucleotide and protein databases. Related nucleic and protein sequences were aligned with ClustalW (Thompson et al., 1994) . The human genome viewer (www.ncbi.nlm.nih.-gov) was used to localize the SMAGP gene on the human genome and the exon/intron structure was identified with the SIM4 computer program (Florea et al., 1998) . Syngenic conservation between rat and human chromosomes was retrieved from the Rat Genome Database Web Site (http:// rgd.mcw.edu/, Medical College of Wisconsin, Milwaukee, Wisconsin). The Protparam tool program on the Expasy Molecular Biology Server (http://www.expasy.ch/tools/) was used to predict the molecular weight and pI of the SMAGP protein. The program Prosite from the same server was used to predict phosphorylation sites.
Further sequence analyses were performed with programs of the GCG sequence analysis package (Wisconsin Package Version 10.2, Genetics Computer Group (GCG), Madison, WI, USA). Consensus sequences were identified by alignments of EST with QuickAssm. Translation of nucleotide sequences into proteins was performed with the algorithm Translate. The hydrophobic transmembrane domain of SMAGP was identified by the Pepplot program. We used different programs of the Center For Biological Sequence Analysis Server (http:// www.cbs.dtu.dk/) to analyse the SMAGP amino-acid sequence. Signal anchor prediction was performed with the algorithm SignalP-HMM (Nielsen et al., 1999) . NetNGlyc (Jensen et al., 2002) , and NetOGlyc (Hansen et al., 1995) programs were used to predict potential N-glycosylation and O-glycosylation sites, respectively.
Deglycosylation assay
Enzymatic deglycosylation experiments were performed with 100 mg or less of total cell lysate denatured at 1001C for 5 min in reaction buffer (0.05 mM sodium phosphate, pH 7) and denaturation buffer (2% SDS, 1 M b-mercaptoethanol). Triton X-100 was then added to the solution to a final concentration of 10%. The enzymes N-glycosidaseF (PNGaseF) (Roche Diagnostics GmbH), Sialidase (Roche Diagnostics GmbH), and O-glycosidase (Sigma, Steinheim, Germany) were added to a final concentration of 100, 100 and 25 mU/ml, respectively, in a total volume of 50 ml. The samples were incubated for 3 h at 371C. Human transferrin, alpha1-acid and RNaseB glycoproteins (Roche Diagnostics GmbH) were used as positive controls for PNGaseF activity, analysed on SDS-PAGE under reducing conditions, and visualized by Coomassie blue staining. After deglycosylation reactions, SMAGP was analysed by Western blotting with rabbit anti-SMAGP antibody.
Antibodies and Western blotting
Rabbit polyclonal antibody anti-SMAGP was generated by Eurogentech S.A. (Herstal, Belgium). The synthetic peptide ESDLAKGSEKEEYFI, corresponding to residues 83-97 of hSMAGP, was coupled to KLH (keyhole limpet hemocyanin) and injected into rabbits. Immunoreactive sera against the synthetic peptide were affinity-purified. Anti-synCAM/ NECL2 antibody directed against the synthetic peptide NNSEEKKEYFI was purchased (Novus Biologicals Inc., CO, USA).
For Western blotting, proteins were extracted with RIPA buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing a protease inhibitor mixture (Complete EDTA free protease Inhibitors, Roche Diagnostics GmbH, Mannheim, Germany). Polyacrylamide gel electrophoresis was performed under reducing conditions using NuPAGE 12% Bis-Tris gel (Invitrogen, Carlsbad, USA) and NuPAGE MES SDS running buffer (Invitrogen). Gels were semi-dry blotted to a nitrocellulose membrane and blocked in TBS buffer (100 mM Tris-Cl pH 7.5, 150 mM NaCl) plus 5% nonfat dry milk (Merck, Darmstadt, Germany). After incubation with rabbit anti-SMAGP diluted 1 : 5000 as primary antibody, membranes were washed in TBS buffer with 0.1% Tween 20, incubated with horseradish peroxidase-conjugated anti-rabbit (Roche Diagnostics GmbH) as secondary antibody and washed again. Antibody detection was performed using enhanced chemiluminescence (Lumilight PLUS Western blotting substrate, Roche Diagnostics GmbH).
Immunohistochemistry
Tissues were fixed in phosphate-buffered formalin (4%). Immunohistochemical analysis was performed on paraffinembedded tissue sections using a peroxidase-antiperoxidase system (DAKO, Carpinteria, CA, USA) for the revelation as previously described (Re´gnier et al., 1995) . Anti-SMAGP antibody was used at 1 : 1000 dilution.
Abbreviations PDZ, postsynaptic density protein, disc-large, zonulin-1; SH3, Src homology 3; MAGUK, membrane-associated guanylate kinase homologue; EST, expressed sequence tag; ORF, open reading frame.
